Abstract
The importance of hypertension treatment has expanded beyond blood pressure management
to include additional risk factors, mainly diabetes. It was considered of interest
to test the effect of telmisartan, an angiotensin receptor 1 antagonist and peroxisome
proliferator activator receptor–γ partial agonist, on Cohen-Rosenthal diabetic hypertensive nonobese (CRDH) rats, a
unique model combining both pathologies. Its effect was examined on fat-derived and
inflammatory agents in CRDH. To determine the extent of the drug's peroxisome proliferator
activator receptor–γ modulating beneficial metabolic actions, results were compared with those obtained
with valsartan and rosiglitazone in CRDH and Cohen diabetic rat (CDR). Telmisartan
and valsartan were given in drinking water at 3 and 12 mg/kg/d, whereas rosiglitazone
(3 mg/kg/d) was given as food admixture for a period of 5 months. Blood pressure,
glucose, insulin, adiponectin, leptin, and tumor necrosis factor α were examined. Telmisartan and valsartan significantly (P < .01) reduced blood pressure, whereas telmisartan and rosiglitazone considerably
reduced blood glucose levels to normoglycemic levels (P < .01) in these 2 strains. Insulin levels were not affected by telmisartan and valsartan
but were slightly reduced by rosiglitazone in CDR. In contrast to valsartan, adiponectin
was significantly (60%, P < .01) increased by telmisartan in both CDR and CRDH, whereas rosiglitazone induced
a 60% and 180% increase in CRDH and CDR animals, respectively, on day 30 of treatment.
Co-treatment with GW9662 averted telmisartan-induced rise of adiponectin. Tumor necrosis
factor α declined in telmisartan-treated rats, less so with rosiglitazone, but not valsartan.
Telmisartan also induced downsizing of epididymal adipocytes compared with valsartan.
Leptin levels were significantly increased by valsartan (P < .05) but reduced by telmisartan and rosiglitazone. The telmisartan-induced increase
in adiponectin was most probably associated with a decrease in glucose and tumor necrosis
factor α levels. Therefore, in addition to its hypotensive effect, telmisartan demonstrated
beneficial thiazolidinedione-like effects.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.Clin Res Cardiol. 2008; 97: 418-431
- New treatment strategies for patients with hypertension and insulin resistance.Am J Med. 2006; 119: S24-S30
- Angiotensin blockade prevents type 2 diabetes by formation of fat cells.Hypertension. 2002; 40: 609-611
- Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.Intern Med. 2007; 46: 1331-1336
- Telmisartan in the treatment of Cohen-Rosenthal diabetic hypertensive rats: the benefit of PPAR-gamma agonism.Clin Exp Hypertens. 2007; 29: 419-426
- Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.J Cardiovasc Pharmacol Ther. 2007; 12: 145-152
- The Cohen diabetic (non–insulin-dependent) hypertensive rat model. Description of the model and pathologic findings.Am J Hypertens. 1993; 6: 989-995
- Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.Hypertension. 2006; 47: 1003-1009
- Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.Am J Hypertens. 2004; 17: 749-756
- Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.Diab Vasc Dis Res. 2007; 4: 117-123
- Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats.Exp Toxicol Pathol. 2009;
- Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.J Hypertens. 2008; 26: 964-972
- Effect of telmisartan on nitric oxide–asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.Hypertension. 2008; 51: 696-703
- Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.Cardiovasc Res. 2006; 72: 184-190
- Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.Vascul Pharmacol. 2006; 45: 154-162
- Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.Circulation. 2004; 109: 2054-2057
- Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.Am J Physiol Endocrinol Metab. 2007; 293: E91-95
- Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.Hypertens Res. 2008; 31: 601-606
- Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.Diabetes Care. 2005; 28: 757-758
- Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.Hypertens Res. 2006; 29: 849-856
- Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.Hypertension. 1997; 29: 1260-1264
- Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation.Biochem Biophys Res Commun. 2007; 356: 1024-1030
- Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients.Cardiovasc Drugs Ther. 2007; 21: 317-318
- Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.Metabolism. 2008; 57: 1473-1478
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care. 2000; 23: 57-63
- Review: peroxisome proliferator-activated receptor gamma and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism.J Clin Endocrinol Metab. 2007; 92: 386-395
- PPARs and fibrosis.Nippon Rinsho. 2005; 63: 597-602
- Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1, IL-6 in spontaneously hypertensive rats (SHR).Pharmacol Rep. 2006; 58: 711-719
- Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats.Hypertens Res. 2008; 31: 737-743
- Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy.Am J Pathol. 2008; 172: 1411-1418
- beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes.Life Sci. 2007; 80: 592-599
- Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.Am J Cardiol. 2007; 100: 1625-1629
- Adiponectin: a novel adipokine linking adipocytes and vascular function.J Clin Endocrinol Metab. 2004; 89: 2563-2568
- Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.Circulation. 2000; 102: 1296-1301
- Hypoadiponectinemia as a marker of adipocyte dysfunction–part II: the functional significance of low adiponectin secretion.J Cardiometab Syndr. 2007; 2: 288-294
- Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.J Hypertens. 2006; 24: 1809-1816
- Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.Hypertension. 2009; 54: 782-787
- PPARgamma-activating angiotensin type–1 receptor blockers induce adiponectin.Hypertension. 2005; 46: 137-143
- Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.Hypertension. 2004; 43: 993-1002
- Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.Hypertension. 2006; 48: 51-57
- Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.Am J Hypertens. 2007; 20: 431-436
- Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity.Obes Res. 2005; 13: 1476-1484
- Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents.Int J Obes Relat Metab Disord. 2004; 28: 470-475
- Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women.Eur J Endocrinol. 2002; 147: 173-180
Article info
Publication history
Published online: January 14, 2010
Accepted:
November 17,
2009
Received:
July 7,
2009
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
